Mendelian Susceptibility to Mycobacterial Disease: The First Case of a Diagnosed Adult Patient in the Czech Republic.

IF 0.7 Q4 IMMUNOLOGY
Case Reports in Immunology Pub Date : 2020-12-19 eCollection Date: 2020-01-01 DOI:10.1155/2020/8836685
Miroslav Prucha, Hana Grombirikova, Pavel Zdrahal, Marketa Bloomfield, Zuzana Parackova, Tomas Freiberger
{"title":"Mendelian Susceptibility to Mycobacterial Disease: The First Case of a Diagnosed Adult Patient in the Czech Republic.","authors":"Miroslav Prucha,&nbsp;Hana Grombirikova,&nbsp;Pavel Zdrahal,&nbsp;Marketa Bloomfield,&nbsp;Zuzana Parackova,&nbsp;Tomas Freiberger","doi":"10.1155/2020/8836685","DOIUrl":null,"url":null,"abstract":"<p><p>We present a case of a 42-year-old woman with Mendelian susceptibility to mycobacterial disease. The disease was diagnosed at an adult age with relatively typical clinical manifestations; the skeleton, joints, and soft tissues were affected by nontuberculous mycobacteria: <i>Mycobacterium lentiflavum</i>, <i>M. kansasii</i>, and <i>M. avium</i>. A previously published loss-of-function and functionally validated variant NM_000416.2:c.819_822delTAAT in <i>IFNGR1</i> in a heterozygous state was detected using whole-exome sequencing. After interferon-<i>γ</i> therapy was started at a dose of 200 <i>µ</i>g/m<sup>2</sup> three times a week, there was significant clinical improvement, with the need to continue the macrolide-based combination regimen. In the last 4 months, she has been in this therapy without the need for antibiotic treatment.</p>","PeriodicalId":42865,"journal":{"name":"Case Reports in Immunology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2020-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769627/pdf/","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/8836685","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 4

Abstract

We present a case of a 42-year-old woman with Mendelian susceptibility to mycobacterial disease. The disease was diagnosed at an adult age with relatively typical clinical manifestations; the skeleton, joints, and soft tissues were affected by nontuberculous mycobacteria: Mycobacterium lentiflavum, M. kansasii, and M. avium. A previously published loss-of-function and functionally validated variant NM_000416.2:c.819_822delTAAT in IFNGR1 in a heterozygous state was detected using whole-exome sequencing. After interferon-γ therapy was started at a dose of 200 µg/m2 three times a week, there was significant clinical improvement, with the need to continue the macrolide-based combination regimen. In the last 4 months, she has been in this therapy without the need for antibiotic treatment.

孟德尔对分枝杆菌疾病的易感性:捷克共和国确诊成人患者的第一例。
我们报告一例42岁女性与孟德尔易感性分枝杆菌疾病。本病诊断于成年,临床表现较为典型;骨骼、关节和软组织受到非结核分枝杆菌:慢黄分枝杆菌、堪萨斯分枝杆菌和鸟分枝杆菌的影响。先前发布的功能缺失和功能验证的变体NM_000416.2:c。采用全外显子组测序检测IFNGR1中处于杂合状态的819_822delTAAT。干扰素γ治疗开始后,剂量为200µg/m2,每周3次,有显著的临床改善,需要继续以大环内酯为基础的联合治疗方案。在过去的4个月里,她一直在接受这种治疗,不需要抗生素治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
14
审稿时长
15 weeks
期刊介绍: Case Reports in Immunology is a peer-reviewed, Open Access journal that publishes case reports and case series related to allergies, immunodeficiencies, autoimmune diseases, immune disorders, cancer immunology and transplantation immunology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信